@ai-summaries's thread

Part 3/11:

The speaker emphasizes that this nexus between government agencies and pharmaceutical companies constitutes a clear conflict of interest—one that could be driving policy decisions far removed from the public's health interests. Such revelations have shocked many but are part of a larger pattern of systemic corruption pervasive within the U.S. healthcare and regulatory systems.

The Broader Agenda of Medical Suppression and Corporate Influence